Navigation Links
New Hepatitis C Drugs Fuel Demand for Molecular IVD Products
Date:2/2/2017

ROCKVILLE, Md., Feb. 2, 2017 /PRNewswire/ -- Hepatitis C is a robustly growing market for both IVD and pharmaceutical players in the developed world. Hepatitis C pharmaceutical growth is hedged by pricing pressures as new players seek to undercut the market leader Gilead Sciences. Newer antivirals introduced first by Gilead in 2014 can cure even acute hepatitis C infections in many cases. The leading market barrier has been the price of therapy, but price cutting is expected eventually in order to maximize market penetration and as a result of competitive pressures. Antiviral treatment regimens are continued or concluded based on repeated testing of patient HCV levels or viral load.  Kalorama covered HCV testing markets along with a wide range of molecular diagnostic applications in its report, The World Market for Molecular Diagnostics, 7th EditionFind the report at: https://www.kaloramainformation.com/Molecular-Diagnostics-Edition-10595682/.

"The combination of Medicare eligibility for hepatitis C patients, higher screening activity and effective therapies has grown HCV viral load test volumes in the United States," said Emil Salazar, analyst for Kalorama Information in a recent blog post

Kalorama Information Logo. (PRNewsFoto/Kalorama Information) (PRNewsFoto/Kalorama Information)
Kalorama Information Logo. (PRNewsFoto/Kalorama Information) (PRNewsFoto/Kalorama Information)

The introduction of new, more effective therapies has coincided with rising hepatitis C patient volumes in U.S. healthcare. Hepatitis C is more prevalent among older U.S. individuals, particularly those of the "baby boomer" generation (born 1945-1965), than younger generations. According to one estimate from the National Health and Nutrition Examination Survey (NHANES), HCV can be found in between 3% and 5% of all U.S. individuals born in the 1950s. For comparison, HCV prevalence for individuals born in the 1940s and 1960s averaged roughly 2%. The higher rate of hepatitis C infection among baby boomers is believed to be a result of blood transfusion-transmitted infections (TTIs) and past intravenous drug use. Hepatitis screening of older patients has been implemented in much of U.S. healthcare to catch asymptomatic and mildly symptomatic cases.

Kalorama said the volume of viral load tests for hepatitis C accepted for payment under Medicare Part B rose from approximately 65,000 procedures in 2010 to nearly 190,000 procedures in 2015. Kalorama Information projects the number of HCV-infected U.S. individuals newly eligible for Medicare (aged 65 during the year) will increase from over 90,000 in 2015 to more than 170,000 in 2020. Medicare coverage of hepatitis C therapies has improved in the past several years, and some private insurers are also likely to follow suit for older patients more at risk of complications from disease progression.

Kalorama details more information in its blog piece on Hepatitis C testing.  http://www.kaloramainformation.com/Content/Blog/2017/01/27/New-Therapies-Risk-Factors-Drive-Hepatitis-C-Diagnostics

About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on www.marketresearch.com and www.profound.com.  

We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog on our company website.  

Please link any media or news references to our reports or data to http://www.kaloramainformation.com/.

Press Contact:
Bruce Carlson
212 807 2262
bcarlson@marketresearch.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/new-hepatitis-c-drugs-fuel-demand-for-molecular-ivd-products-300401365.html


'/>"/>
SOURCE Kalorama Information
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. AbbVie Submits New Drug Application to U.S. FDA for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C
2. Arcturus Therapeutics Announces Collaboration with Takeda Pharmaceuticals to Develop RNA-based Therapeutics for the Treatment of Nonalcoholic Steatohepatitis (NASH)
3. Yisheng Biopharma Announces Completion of Phase I Clinical Study of a Novel Hepatitis B Vaccine with PIKA Adjuvant
4. Hepatitis E Diagnostic Tests Market Worth 60.4 Million USD by 2024: Fueled by Lack of Potable Water, Hepatitis E Hyperendemicity to Drive Growth, Reports TMR
5. Staaten wollen virale Hepatitis bis 2030 eliminieren
6. Governments on Track to Eliminate Viral Hepatitis by 2030
7. Global Hepatitis C Market and Competitive Landscape Report 2016-2020 - Research and Markets
8. Diplomat Celebrates World Hepatitis Month with National Multimedia Campaign
9. Global HCV Market: Gilead Sciences, AbbVie, J&J and Bristol-Myers Squibb Featured in 2016 Hepatitis C Virus Edition Report
10. Biotron Phase 2 Hepatitis C Trial Success
11. Eiger Announces Completion of Enrollment of Phase 2 LOWR HDV - 4 (LOnafarnib With Ritonavir in Hepatitis Delta Virus - 4) Study at Hannover Medical School
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2017)... 3, 2017  Opioid addiction and other drugs of ... costs and threatening outcomes, were problems taken on directly ... industry that support them, met this week. This according ... that drugs of abuse, procalcitonin and acute kidney injury ... organization,s 69th meeting in San Diego, CA. ...
(Date:8/2/2017)... WASHINGTON , Aug. 2, 2017 CaryRx, a ... same day delivery service for patients in the ... the traditional retail pharmacy by providing delivery of medications through ... scheduled for future delivery or delivered within one hour to ... "We are excited to bring this invaluable service to ...
(Date:7/31/2017)... 7D Surgical, developer of ground breaking surgical navigation technologies, announced ... to support its strategic sales plan in Maryland ... 7D Surgical has entered into an exclusive sales representative agreement ... within those markets. ... Spartan Medical Purchases 7D Surgical ...
Breaking Medicine Technology:
(Date:8/22/2017)... ... 22, 2017 , ... Pivot Point Consulting, a ... as the firm’s new Consulting Services Executive. Mr. Tisch will oversee all aspects ... assisting clients with initial vendor selection and pre-implementation planning through go-live support and ...
(Date:8/22/2017)... ... August 22, 2017 , ... “To Walk Away”: a ... B17 bomber named Edward Koontz. “To Walk Away” is the creation of published author, ... published over two hundred manuscripts in chemistry and religion, as well as four novels. ...
(Date:8/22/2017)... Raleigh, North Carolina (PRWEB) , ... August 22, ... ... senior strategic advisor. Mr. Stewart is the Founder and Managing Member for t4 ... elements that have become critical to his definition of “success”: physician leadership development, ...
(Date:8/21/2017)... ... 22, 2017 , ... Nanoparticle research provides an exciting path ... learning and implementing best practices for containment using ventilated safety enclosures, many of ... a better understanding of a method for safely testing nanotechnology hoods. They will ...
(Date:8/21/2017)... , ... August 21, 2017 , ... Five chefs from ... awareness for Alzheimer’s Family Center. , Guests will be able to vote for ... Plaza, Braised Lamb Shank with Fennel Dill Salad, Feta Cheese Sauce & Garlic Pita ...
Breaking Medicine News(10 mins):